28. 全身性アミロイドーシス Systemic amyloidosis Clinical trials / Disease details

臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05066607 (ClinicalTrials.gov)	February 11, 2022	24/8/2021	IsatuximabPlus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VG ...	A Phase 2, Open Label, Multicenter, Single-stage Study to Evaluate the Efficacy of IsatuximabPlus Po ...	AL Amyloidosis	Drug: Isatuximab	Intergroupe Francophone du Myelome	Sanofi;Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	46	Phase 2	France
2	NCT04754945 (ClinicalTrials.gov)	April 28, 2021	9/2/2021	Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis	Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy	AL Amyloidosis	Drug: Bortezomib;Drug: Cyclophosphamide;Drug: Dexamethasone;Biological: Isatuximab	Emory University	Sanofi;National Cancer Institute (NCI)	Recruiting	18 Years	N/A	All	25	Phase 1	United States
3	NCT03499808 (ClinicalTrials.gov)	March 8, 2018	9/4/2018	S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis	A Phase II Study of Isatuximab(SAR650984) (NSC-795145) for Patients With Previously Treated AL Amylo ...	Amorphous, Eosinophilic, and Acellular Deposit;Constipation;Diarrhea;Early Satiety;Gastrointestinal ...	Biological: Isatuximab;Other: Laboratory Biomarker Analysis	Southwest Oncology Group	National Cancer Institute (NCI)	Active, not recruiting	18 Years	N/A	All	43	Phase 2	United States

First Previous1Next Last